ArticleMolecular biology reports2026
SERPINB5 promotes pancreatic adenocarcinoma progression through FBXO32-mediated regulation of epithelial-mesenchymal transition.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundPancreatic adenocarcinoma (PAAD) is a highly aggressive malignancy. This study aimed to investigate the clinical significance and biological functions of SERPINB5 in PAAD.
methodsDifferentially expressed genes were screened from the TCGA-PAAD, GSE32676, and GSE101448 datasets. The candidate gene SERPINB5 was identified using LASSO Cox regression and receiver operating characteristic (ROC) curve analysis. SERPINB5 expression in PAAD cell lines was validated via in vitro experiments. The effects of silencing SERPINB5 on cellular phenotypes and epithelial-mesenchymal transition (EMT) were assessed using CCK-8, colony formation, and Transwell assays, as well as immunofluorescence and Western blotting. Co-immunoprecipitation (Co-IP) and rescue experiments were conducted to explore the relationship between SERPINB5 and FBXO32.
resultsA risk model identified seven candidate prognostic genes, including SERPINB5. Independent single-gene ROC analysis assessed its ability to discriminate PAAD tumors from normal pancreatic tissues across three transcriptomic datasets, with areas under the curve (AUC) values of 0.851, 0.966, and 0.965. Expression analysis revealed consistently high SERPINB5 levels in both PAAD tissues and cell lines. Functional studies showed that silencing SERPINB5 inhibited PAAD cell proliferation, colony formation, migration, and invasion. Mechanistic studies indicated that SERPINB5 knockdown upregulated E-cadherin expression while downregulating Vimentin and N-cadherin levels. Co-IP experiments confirmed a physical interaction between SERPINB5 and FBXO32, and SERPINB5 knockdown resulted in reduced FBXO32 expression. Furthermore, FBXO32 overexpression reversed the malignant phenotypes and EMT-related changes caused by SERPINB5 silencing.
conclusionOur findings indicate that SERPINB5 may be a candidate diagnostic and prognostic marker for PAAD. Functionally, the SERPINB5/FBXO32 axis appears to promote PAAD progression, at least partly, through epithelial-mesenchymal transition regulation.
Indexed as
Identifiers
42878980What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.